Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trial.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
11
2021
accepted:
12
05
2022
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
We aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients. In this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen. We randomly assigned patients to receive intravenous anakinra plus optimized standard of care (oSOC) vs. oSOC alone. The primary outcome was treatment success at day 14 defined as patient alive and not requiring mechanical ventilation or extracorporeal membrane oxygenation. Between 27th April and 6th October 2020, we enrolled 71 patients (240 patients planned to been enrolled): 37 were assigned to the anakinra group and 34 to oSOC group. The study ended prematurely by recommendation of the data and safety monitoring board due to safety concerns. On day 14, the proportion of treatment success was significantly lower in the anakinra group 70% (n = 26) vs. 91% (n = 31) in the oSOC group: risk difference-21 percentage points (95% CI, -39 to -2), odds ratio 0.23 (95% CI, 0.06 to 0.91), p = 0.027. After a 28-day follow-up, 9 patients in the anakinra group and 3 in the oSOC group had died. Overall survival at day 28 was 75% (95% CI, 62% to 91%) in the anakinra group versus 91% (95% CI, 82% to 100%) (p = 0.06) in the oSOC group. Serious adverse events occurred in 19 (51%) patients in the anakinra group and 18 (53%) in the oSOC group (p = 0·89). This trial did not show efficacy of anakinra in patients with COVID-19. Furthermore, contrary to our hypothesis, we found that anakinra was inferior to oSOC in patients with moderate COVID-19 pneumonia.
Identifiants
pubmed: 35925914
doi: 10.1371/journal.pone.0269065
pii: PONE-D-21-35547
pmc: PMC9351999
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0269065Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Respir Med. 2021 Mar;9(3):295-304
pubmed: 33493450
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Ann Rheum Dis. 2020 Oct;79(10):1381-1382
pubmed: 32376597
Nat Med. 2021 Oct;27(10):1752-1760
pubmed: 34480127
Lancet Rheumatol. 2020 Jun;2(6):e358-e367
pubmed: 32373790
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
Rheumatology (Oxford). 2019 Nov 1;58(Suppl 6):vi9-vi22
pubmed: 31769856
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32886755
Semin Immunol. 2013 Dec 15;25(6):469-84
pubmed: 24275598
Intensive Crit Care Nurs. 2016 Dec;37:62-67
pubmed: 27386753
Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):18951-18953
pubmed: 32699149
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1
pubmed: 32411313
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Lancet Rheumatol. 2020 Jul;2(7):e393-e400
pubmed: 32835245
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990